Global Human Papillomavirus Vaccine Market Size study, by Type (Bivalent, Quadrivalent, Nonavalent), Indication (Cervical Cancer, Anal Cancer, Penile Cancer, Oropharyngeal Cancer, Genital Warts, and Others), and Regional Forecasts 2022-2028

Global Human Papillomavirus Vaccine Market Size study, by Type (Bivalent, Quadrivalent, Nonavalent), Indication (Cervical Cancer, Anal Cancer, Penile Cancer, Oropharyngeal Cancer, Genital Warts, and Others), and Regional Forecasts 2022-2028

Global Human Papillomavirus Vaccine Market is valued at approximately USD XXX million in 2021 and is anticipated to grow with a healthy growth rate of more than 7.5% over the forecast period 2022-2028. The virus known as the human papillomavirus (HPV) spreads through interaction with others who have the same complexion. There are more than 100 different forms of HPV, over 40 of which have been sexually transmitted and can harm your genital area, mouth, or neck. According to the Centers for Disease Control and Prevention (CDC), HPV is the most common illness. Because it is so common, even those who have few sexual partners may eventually get some of its many forms. The market growth driven by key factors such as increasing initiatives by Government & Private Organizations for Early Screening & Vaccination and approval of New HPV Vaccines. According to data published by UNICEF in 2018, the organisation received more than 12.9 million doses of the human papillomavirus (HPV) vaccination between 2013 and 2017. Additionally, UNICEF procured 16 percent of doses for self-financing middle-income countries and 84 percent of doses for Gavi, the Vaccine Alliance (Gavi)-supported nations (MICs). Furthermore, Cancer is the second most prevalent cause of cancer-related mortality globally, accounting for about 300,000 fatalities yearly, according to the WHO. It is also the third most common disease in women. Therefore, the market is anticipated to see rapid expansion throughout the projected period because of the growing incidence of cervical cancer. However, stringent Regulation impedes the growth of the market over the forecast period of 2022-2028.

The key regions considered for the Global Human Papillomavirus Vaccine Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is dominating the market growth owing to stringent Regulation and rising cases are expected to boost the growth of the market. On the other side, APAC is the fastest growing region due to increase in major companies' investments in setting up vaccine manufacturing units and increase in major companies' investments in setting up vaccine manufacturing units.

Major market players included in this report are:
Merck & Co., Inc.,
Walvax Biotechnology Co., Ltd
GlaxoSmithKline Plc
Wantai BioPharm
INOVIO Pharmaceuticals
Serum Institute of India Pvt. Ltd.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Application offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:
Bivalent
Quadrivalent
Nonavalent
By Indication:
Cervical Cancer
Anal Cancer
Penile Cancer
Oropharyngeal Cancer
Genital Warts
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Human Papillomavirus Vaccine Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Merck & Co., Inc.,
Walvax Biotechnology Co., Ltd
GlaxoSmithKline Plc
Wantai BioPharm
INOVIO Pharmaceuticals
Serum Institute of India Pvt. Ltd.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.